ALK TKI Side Effects and Acquired Resistance – 2022 Program: Targeted Therapies Forum

Addressing the challenges of ALK TKIs, this insightful session from the 2022 Targeted Therapies Forum is brought to you by the distinguished Dr. Millie Das. In the vast landscape of cancer treatments, ALK TKIs have shown significant promise, but like all therapies, they come with their considerations.

Huge appreciation to our generous sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Their commitment drives progress in the ever-evolving realm of oncology.

For a deeper dive into the advancements and discussions in cancer treatment, explore http://cancerGRACE.org/. Engage and share with our expert community at https://cancergrace.org/forum.